Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Fig. 3

ACR response rates for abatacept administered in combination with (a) MTX vs any one non-MTX csDMARD (pooled analysis) and (b) individual csDMARDs at 6 months in the ATTAIN study. Excludes patients on multiple background csDMARDs. Error bars show 95% CI. ABA abatacept, ACR20/50/70, ≥ 20%/≥ 50%/≥ 70% improvement in American College of Rheumatology criteria, AZA azathioprine, csDMARD conventional synthetic disease-modifying antirheumatic drug, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, SSZ sulfasalazine

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us